Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05781399 · ClinicalTrials.gov registry record · Phase 1
First-in-Human, Multiple Part Clinical Study of JNT-517 in Healthy Participants and in Participants With Phenylketonuria
A Phase 1 study of Phenylketonuria, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Active
- Registry status
- Phase 1
- Development phase
- 135
- Enrollment target
- 15
- Study locations
NCT05781399 is a Phase 1 study of Phenylketonuria that is active but no longer recruiting, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 135 participants, above the 88-participant average among 12 other Phenylketonuria trials with a reported enrollment target (53% higher). The trial reports 15 study locations across 12 states.
The verdict
NCT05781399, a Phase 1 study of Phenylketonuria, is active but no longer recruiting, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 135 participants
- Enrollment target
- 15
- Study locations
Study Summary
The goal of Parts A and B of this Phase 1/2, first-in-human, randomized study is to assess the safety, tolerability, and pharmacokinetics (PK) of single (SAD) and multiple (MAD) ascending doses of oral JNT-517 in healthy participants. In Part C, the goal is to evaluate the differences in bioavailability between a tablet and suspension formulation of JNT-517 and the food effect in healthy volunteers. All participants in Part C will receive JNT-517. The goal of Part D is to assess the safety, tolerability, PK, and effect on urinary Phe and other amino acids of JNT-517 in participants with phenylketonuria (PKU). Participants in Part D will receive either JNT-517 or placebo and will be blinded to their treatment assignment. The study consists of 6 parts: * Part A: SAD in healthy participants -randomized, double-blind, placebo-controlled * Part B: MAD in healthy participants (14 days)-randomized, double-blind, placebo-controlled * Part C: Relative bioavailability of 2 formulations and food effect in healthy participants-randomized, open-label * Part D: Phase 2 in participants with PKU (4 weeks)-randomized, double-blind, placebo-controlled * Part E: Phase 2 in participants with PKU (4 weeks) open label * Part F: SAD Phase 1 in healthy participants, randomized, double-blind, placebo-controlled In each part, participants will complete a Screening Period, a Treatment Period, and a Follow-up Period for safety.
Conditions Studied
Interventions
- DRUG JNT-517 Tablet
- DRUG Placebo Tablet
- DRUG JNT-517 Suspension
- DRUG Placebo Suspension
Study Locations (15)
Florida
- University of Florida College of Medicine - Gainesville
- University of South Florida - Tampa
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
- UPMC Children's Hospital of Pittsburgh - Pittsburgh
Texas
- UT Southwestern Medical Center - Dallas
- University of Texas Health Science Center at Houston - Houston
Georgia
- Rare Disease Research - Atlanta
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago
Nebraska
- University of Nebraska Medical Center - Omaha
Oregon
- Oregon Health & Sciences University - Portland
Utah
- Utah Health - The University of Utah Hospital - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2022-10-31 |
| Est. Completion | 2025-12-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05781399
The ClinicalTrials.gov registry entry for NCT05781399 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 135 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 88-participant average among 12 other Phenylketonuria trials with a reported enrollment target (53% higher). The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Phenylketonuria appearing as the primary indexed condition, and to 4 interventions - of which JNT-517 Tablet is the first listed.
NCT05781399 reports 15 study locations spanning 12 distinct geographic areas - top geographies include Florida, Pennsylvania, Texas.
Frequently Asked Questions
What is clinical trial NCT05781399 about?
NCT05781399 is a clinical study titled "First-in-Human, Multiple Part Clinical Study of JNT-517 in Healthy Participants and in Participants With Phenylketonuria". The goal of Parts A and B of this Phase 1/2, first-in-human, randomized study is to assess the safety, tolerability, and pharmacokinetics (PK) of single (SAD) and multiple (MAD) ascending doses of oral JNT-517 in healthy participants. In Part C, the goal is to evaluate the differences in bioavailabi...
What is the current status of trial NCT05781399?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 135 participants. The study started on 2022-10-31. Estimated completion is 2025-12-15.
What conditions does trial NCT05781399 study?
This clinical trial studies the following conditions: Phenylketonuria.
What interventions are being tested in trial NCT05781399?
The interventions under investigation include: JNT-517 Tablet (DRUG), Placebo Tablet (DRUG), JNT-517 Suspension (DRUG), Placebo Suspension (DRUG).
Who is sponsoring clinical trial NCT05781399?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05781399 being conducted?
This trial has 15 study locations across Florida, Georgia, Illinois, Nebraska, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Phenylketonuria
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1/Phase 2 Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of a Single Intravenous Administration of SAR444836 in Adult Participants With Phenylketonuria
ACTIVE NOT RECRUITING · Phase 1
-
A Phase 1 Study to Evaluate Effects of Sapropterin Dihydrochloride on QTc Intervals in Healthy Adult Subjects
COMPLETED · Phase 1
-
A Study to Evaluate the Safety and Efficacy of JNT-517 in Participants With Phenylketonuria (PKU)
RECRUITING · Phase 3
-
Educational, Social Support, and Nutritional Interventions and Their Cumulative Effect on Pregnancy Outcomes and Quality of Life in Teen and Adult Women With Phenylketonuria
RECRUITING · NA
-
A Study of Sepiapterin in Participants With Phenylketonuria (PKU)
RECRUITING · Phase 3
-
Rapid Drug Desensitization Study in Adults Experiencing Hypersensitivity Reactions to Palynziq
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.